BOSS试验中登记系统与试验特异性死亡数据的一致性与效用比较
本研究基于BOSS试验,比较医疗系统数据(HSD)与试验特异性死亡数据在死亡状态、日期和死因上的一致性,并评估五种数据整合方法对总生存结局的影响。结果显示两种来源总体准确且互补,不同整合方法对治疗效应估计影响不大,联合使用所有数据来源可增强试验结果可靠性。
要点
- HSD与试验特异性死亡状态和日期一致性较高(Cohen's Kappa 0.866)。
- 超过100名参与者死亡状态记录不一致,死亡日期中位差异近一年。
- 五种整合方法对治疗效应估计影响不大,联合数据可增强试验结果。
核心结论
- HSD与试验特异性死亡数据总体准确完整,不同整合方法不影响试验结果,联合使用所有数据来源应被鼓励。
研究设计与样本
- 基于BOSS试验,比较试验特异性与HSD死亡数据在死亡状态、日期和死因上的一致性,并测试五种数据整合方法对总生存的影响。
主要发现
- 死亡状态和日期一致性较高(Cohen's Kappa 0.866,95%CI 0.842至0.889)。
- 超过100名参与者死亡状态记录不一致,死亡日期中位差异340天(IQR 11至865天)。
- 所有整合方法产生相似治疗效应估计,均未改变试验结果。
- 单独使用HSD的风险比为1.01(95%CI 0.85至1.20),试验特异性风险比为0.89(95%CI 0.75至1.06)。
临床怎么用
- 当试验数据与HSD均可获得时,建议联合使用所有数据来源以增强结果可靠性。
- 不同数据整合方法对治疗效应估计影响不大,可根据实际情况选择合适方法。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Healthcare Systems Data (HSD) are increasingly used in RCTs to supplement data required for clinical trial outcomes; however, the true quality and utility of this data remain unclear. In clinical trials when data discrepancies are present, rules of data integration must be in place to handle the differences; however, there is little evidence as to the best approach for how these principles are set. The purpose of this study is to conduct a comprehensive data utility comparison of HSD mortality data and trial-specific mortality data collected in the BOSS trial. METHODS: Trial-specific and HSD mortality data collected in the BOSS trial were compared to assess levels of agreement between death status, death dates, and causes of death. Potential sources of data inconsistencies were examined to determine underlying patterns between HSD and trial-specific data discrepancies. HSD and trial-specific data were combined through five data integration approaches to assess their impact on the primary outcome of overall survival. RESULTS: Death status and death dates were similar between trial-specific and HSD data (Cohen's Kappa statistic 0.866, 95% CI 0.842 to 0.889); however, more than 100 participants were recorded with inconsistent death statuses, and the median difference between different death dates was almost a year (340 days, IQR: 11 to 865 days). All data integration approaches contributed to similar treatment effect estimates, and none changed the results of the trial. The treatment effect estimations from either source exclusively were comparable (HSD Hazard Ratio 1.01, 95% CI 0.85 to 1.20; trial-specific Hazard Ratio 0.89, 95% CI 0.75 to 1.06), and when both sources were integrated to produce hazard ratio estimates, the results were almost identical regardless of the approach taken. CONCLUSIONS: In a direct comparison of mortality data between HSD and trial-specific data for the BOSS trial, both sources were mostly accurate and complete. Trial results were not impacted by different approaches of data integration and were generally strengthened by combining all data sources. This should be always encouraged when trial data and HSD are both collected. TRIAL REGISTRATION: ISRCTN54190466. Registered on 8 January 2008.
引用
- Zimmermann A, Old O, Barr H, et al. Agreement and utility between registry and trial mortality data - a data utility comparison in the BOSS trial. Trials. 2026. PMID: 41840641. doi:10.1186/s13063-026-09605-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。